Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
17.69
+0.98 (5.90%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Travere Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Travere Therapeutics stock have an average target of 33.75, with a low estimate of 20 and a high estimate of 47. The average target predicts an increase of 90.84% from the current stock price of 17.69.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Travere Therapeutics stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 5 |
| Buy | 6 | 6 | 6 | 8 | 8 | 7 |
| Hold | 3 | 3 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 12 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 23, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $47 | Strong Buy | Reiterates | $47 | +165.76% | Apr 14, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $45 → $47 | Strong Buy | Maintains | $45 → $47 | +165.76% | Apr 10, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 3, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $29 → $31 | Strong Buy | Maintains | $29 → $31 | +75.29% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
392.45M
from 233.18M
Increased by 68.31%
Revenue Next Year
610.85M
from 392.45M
Increased by 55.65%
EPS This Year
-1.47
from -4.08
EPS Next Year
1.01
from -1.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 461.9M | 840.2M | 849.4M | ||
| Avg | 392.5M | 610.9M | 712.8M | ||
| Low | 324.5M | 433.7M | 575.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 98.1% | 114.1% | 39.1% | ||
| Avg | 68.3% | 55.7% | 16.7% | ||
| Low | 39.2% | 10.5% | -5.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.59 | 3.47 | 3.39 | ||
| Avg | -1.47 | 1.01 | 1.74 | ||
| Low | -2.39 | -0.96 | 0.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 236.6% | ||
| Avg | - | - | 72.6% | ||
| Low | - | - | -68.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.